Trial Profile
Immunotherapy Combined With Yttrium-90 RadioEmbolization in the Treatment of Colorectal Cancer With Liver Metastases [iRE-C - Clinical Trial]
Status:
Suspended
Phase of Trial:
Phase I/II
Latest Information Update: 16 Nov 2022
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Yttrium-90 (Primary)
- Indications Colorectal cancer; Liver metastases
- Focus Adverse reactions
- Acronyms iRE-C
- 11 Nov 2022 Planned End Date changed from 1 Oct 2022 to 31 Dec 2025.
- 11 Nov 2022 Planned primary completion date changed from 1 Oct 2022 to 31 Dec 2023.
- 18 Aug 2022 Status changed from recruiting to suspended.